Form D · Biotechnology
Recros Medica, Inc.
San Diego, CA · CIK 0001619033
Offering snapshot reported Feb 14, 2019 · SEC filing
- Reported sold
- $4.12M Offering amount: $10M
- Investors reported
- 47 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 21, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 14, 2019 | Initial | $4,121,779 | No comparison | 47 | SEC filing |
| Jul 25, 2017 | Amendment | $4,413,250 | $3,463,250vs Jul 6, 2016 | 44 | SEC filing |
| Aug 23, 2016 | Amendment | $1,365,600 | $1,115,600vs Sep 10, 2014 | 5 | SEC filing |
| Jul 6, 2016 | Initial | $950,000 | No comparison | 6 | SEC filing |
| Sep 10, 2014 | Initial | $250,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-332906
Source: Form D, filed Feb 14, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas A. Albright | Director, Executive |
| Milind K. Ambe, M.D. | Director |
| David F. Hale | Director |
| Mark J. Kerslake | Director |
| Edward Knowlton, M.D. | Director, Executive |
| Cathy L. Mc Carthy | Director |
| Kathleen D. Scott | Executive |
| Christoph Westphal | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3525 Del Mar Heights Road Suite 609
San Diego, CA, 92130
San Diego, CA, 92130